

Date: 14th November, 2018

To,

EMERGE PLATFORM OF NSE
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

Subject: Outcome of Board Meeting held on Wednesday, 14th November, 2018.
SYMBOL: AJOONI

Dear Sir/Madam,

Pursuant to the provisions of Regulations 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors in their meeting held on Wednesday, 14th November, 2018 at 3:30 p.m. and concluded at 3.55 p.m.:

1. Consider and Approved and taken on records the Unaudited Financial Results along with Limited Review Report for the Half Year ended on September 30, 2018 as recommended by the Audit Committee.


Further, we hereby enclose the following:

- a. Unaudited Financial Results for the Half Year ended on September 30, 2018.
 - b. Limited Review Report from the Statutory Auditor of the Company.
2. Considered and approve the **resignation of Mr. Charanjit Singh** from the post of Chief Financial Officer (CFO) of the Company.
 3. Considered and Approve the **Appointment of Mr. Gurmeet Singh**, as Chief Financial Officer (CFO) of the Company.

You are requested to take the same on record and acknowledge receipt.

Thanking You,
Yours Truly,

For Ajooni Biotech Limited
For AJOONI BIOTECH LTD.



Jasjot Singh Director
Managing Director
DIN: 01937631



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

Limited Review Report

Review Report to the Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the accompanying statement of Un-Audited Financial Result of **M/s. Ajooni Biotech Limited** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Half Year ended 30th Sep, 2018 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Un-Audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any martial misstatement.

Date: 14-November-2018
Place: Mohali



For Harjeet Parvesh & Co.
Chartered Accountants

Firm Regn. No. 017437N


CA Suprit Kaur
Partner
M.No 424986

AJOONI BIOTECH LIMITED
CIN : U85190PB2010PLC040162

STATEMENT OF FINANCIAL RESULTS FOR THE HALF YEAR ENDED/ QUARTER ENDED 30TH SEPTEMBER, 2018 (IN LAKHS)

PARTICULARS	Half Year Ended (Unaudited)		Year Ended (Audited)
	30.09.2018	31.03.2018	31.03.2018
1 INCOME FROM OPERATIONS			
A Net Sales/ Income From Operations	1826.06	2176.57	4237.42
B Other Operating Income	1.53	21.05	22.00
TOTAL INCOME FROM OPERATIONS (NET)	1,827.59	2,197.62	4,259.42
2 EXPENSES:			
Cost of Material Consumed	1949.35	1909.10	3755.44
Purchase of Stock-In-Trade	0.00	0.00	0.00
Change In Inventories	-286.23	-3.72	13.48
Employee Benefit Expenses	54.79	52.77	88.15
Depreciation	14.19	15.74	31.48
Preliminary Expenses Written off	0.00	7.04	14.07
Other Expenses (Any Item Exceeding 10% of Other Expenses Relating To Continuing Operations To Be Shown Separately)	70.53	164.36	273.93
TOTAL EXPENSES	1,802.63	2,145.28	4,176.55
PROFIT / (LOSS) FROM OPERATION BEFORE OTHER INCOME, FINANCE COST AND EXCEPTIONAL ITEMS	(1- 24.95)	52.34	82.86
3 2)			
4 Other Income			
PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COST AND EXCEPTIONAL ITEMS (3 + 4)	24.95	52.34	82.86
5			
6 Finance Cost	4.39	10.83	34.07
PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5 + 6)	20.57	41.52	48.79
7			
8 Exceptional Items			
PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7 + 8)	20.57	41.52	48.79
9			
10 TAX EXPENSE:			
(1) Current Tax	0.00	13.08	13.08
(2) Deferred Tax	0.00	-2.90	-2.90
(3) MAT Credit	0.00	0.00	0.00
11 NET PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9+10)	20.57	31.33	38.61
12 Extraordinary Items (Net of Tax ` Expense ____ Lakhs)			
13 NET PROFIT / (LOSS) FOR THE PERIOD (11 + 12)	20.57	31.33	38.61
14 Share of Profit / (loss) of associates *			
15 Minority Interest *			
NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (13 + 14 + 15) *	20.57	31.33	38.61
16			
17 Paid-up equity share capital (Face Value of the Share shall be indicated)	585.50	585.50	585.50
Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	508.86	63.89	63.89
Earnings Per Share (before extraordinary items) (of Rs ____/- each)			
19 (not annualised):			

For AJOONI BIOTECH LTD.

Director

(1)BASIC	0.35	0.54	0.66
(2)DILUTED	0.35	0.54	0.66
Earnings Per Share (after extraordinary items) (of Rs ___/- each)			
19 (not annualised):			
(1)BASIC	0.35	0.54	0.66
(2)DILUTED	0.35	0.54	0.66
* Applicable in the case of consolidated results.			

Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14TH November, 2018.

Place : Mohali

Date : 14.11.2018

**For and on behalf of Board of
Ajooni Biotech Limited**

For AJOONI BIOTECH LIMITED

Jasjot Singh

Director

Director

DIN: 01937631

AJOONI BIOTECH LIMITED
CIN : U85190PB2010PLC040162

STATEMENT OF ASSETS AND LIABILITIES AS ON 30TH SEPTEMBER, 2018

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES	AS ON	AS ON
	30.09.2018	31.03.2018
I. EQUITY AND LIABILITIES		
(1) SHAREHOLDER'S FUND		
(A) SHARE CAPITAL	585.50	585.50
(B) RESERVES AND SURPLUS	529.43	508.86
(C) MONEY RECEIVED AGAINST SHARE WARRANTS	-	-
SUB-TOTAL - SHAREHOLDERS' FUNDS	1,114.93	1,094.36
(2) SHARE APPLICATION MONEY PENDING ALLOTMENT	-	-
(3) MINORITY INTEREST *	-	-
(4) NON CURRENT LIABILITIES		
(A) LONG TERM BORROWINGS	86.37	467.89
(B) DEFERRED TAX LIABILITIES (NET)	-	-
(C) OTHER NON-CURRENT LIABILITIES	216.99	216.99
(D) LONG-TERM PROVISIONS	-	-
SUB-TOTAL - NON-CURRENT LIABILITIES	303.36	684.88
(5) CURRENT LIABILITIES		
(A) SHORT TERM BORROWINGS	61.00	-
(B) TRADE PAYABLE	153.99	115.09
(C) OTHER CURRENT LIABILITIES	12.45	22.37
(D) SHORT TERM PROVISIONS	-	13.08
SUB-TOTAL - CURRENT LIABILITIES	227.44	150.54
TOTAL EQUITY & LIABILITIES	1,645.73	1,929.78
II. ASSETS		
(1) NON CURRENT ASSETS		
(A) FIXED ASSETS		
(i) TANGIBLE ASSETS	102.87	103.55
(B) GOODWILL ON CONSOLIDATION *	-	-
(C) NON CURRENT INVESTMENTS	422.02	601.84
(D) DEFERRED TAX ASSETS (NET)	3.94	3.94
(E) LONG TERM LOANS & ADVANCES	-	-
(F) OTHER NON CURRENT ASSETS	56.39	56.28
SUB-TOTAL - NON-CURRENT ASSETS	585.22	765.62
(2) CURRENT ASSETS		
(A) CURRENT INVESTMENTS	-	-
(B) INVENTORIES	486.14	199.90
(C) TRADE RECEIVABLES	353.22	286.17
(D) CASH AND CASH EQUIVALENTS	17.85	529.69
(E) SHORT TERM LOANS AND ADVANCES	125.36	70.05
(F) OTHER CURRENT ASSETS	77.95	78.35
SUB-TOTAL - CURRENT ASSETS	1,060.51	1,164.17
TOTAL-ASSETS	1,645.73	1,929.78

*APPLICABLE IN THE CASE OF CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

For and on behalf of Board of
Ajooni Biotech Limited
For AJOONI BIOTECH LTD.

Jasjot Singh
Director
DIN: 01937631

Place : Mohali
Date : 14.11.2018